Therapy Detail

Therapy Name Bleomycin + CBP501
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bleomycin Blenoxane BLM
CBP501 CHK1 Inhibitor 14 CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Bleomycin + CBP501 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the combination of Blenoxane (bleomycin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of colorectal cancer, compared to either agent alone (PMID: 17237275). 17237275
Unknown unknown pancreatic cancer not applicable Bleomycin + CBP501 Preclinical - Cell culture Actionable In a preclinical study, the combination of Blenoxane (bleomycin) and CBP501 resulted in increased cell death compared to Blenoxane (bleomycin) alone in a human pancreatic cancer cell line in culture (PMID: 17237275). 17237275
Clinical Trial Phase Therapies Title Recruitment Status